Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin in ASCT Consolidation and Maintenance for Multiple Myeloma
NCT04680468Phase 2Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jun 2021
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by University of Pennsylvania. Started Jun 2021; status: active, not recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04680468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04680468.